2018 Thursday Symposia
Share |



SCCT/ASPC Cardiovascular Disease Prevention Symposium
Thursday, July 12
8am - 3:30pm

Organizing Committee:
Ron Blankstein, MD, FSCCT
Khurram Nasir, MD, MPH, FSCCT
Amit Khera, MD
Parag Joshi, MD, MHS

 Introduction and overview
 8 - 8:10am  Welcome and introductions
 The changing landscape of preventive cardiology: new risk assessment tools and new therapies.
 The latest guidelines and shared decision making
 8:10 - 8:30am  Controversies around the 2017 Lipid Lowering Guidelines
 8:30 - 8:50am  Overview and clinical insights of the 2017 Hypertension Guidelines
 8:50 - 9:10am  Patient education resources and shared decision making in 2018
 9:10 - 9:30am  Panel discussion / cases
 9:30 - 9:45am Break
 How to measure residual risk and emerging therapies for secondary prevention
 9:45 - 10:10am  Keynote address: lowering inflammation in CV disease
 10:15 - 10:35am  Will lowering triglycerides be the answer: insights from current clinical trials
 10:35 - 11am  The role of anticoagulant therapy in lowering CV events
 11 - 11:15am  Panel discussion; Q&A
Challenging lipid/prevention cases: Case-based panel discussion with audience participate
 11:15 - 11:45am  Case 1: A 48 year old with XX
 Case 2: A 32 year old female with XX
 Case 3: A 68 year old male with XX
 11:45am - 12noon  Break/lunch distributed
 Going beyond medicines: How to effectively implement lifestyle therapies
 12noon - 12:40pm  Dietary debate: Plant-based diet vs. Mediterranean diet
 12:40 - 1:05pm  How much, and what kind, of exercise should we prescribe?
 1:05 - 1:25pm  How to give effective dietary advice to patients?
 1:25 - 1:45pm  What is the role of dietary supplements?
 PCSK9 and other novel therapeutics
 2 - 2:15pm  Which patients should be treated with PCSK9 inhibitors in 2018?
 2:15 - 2:30pm  Cost of PCSK9 inhibitors: What are the view points of different stakeholders and how do we achieve balance of value and efficacy?
 2:30 - 2:45 pm  Other novel therapeutics on the horizon
 2:45 - 3pm  Panel discussion
 How should we allocate statins and advanced therapies in cardiovascular disease:  A moderated debate with audience participation  
 3 -3:30pm  Polygenic risk score will tell us who to treat
   Imaging will guide treatment
   Panel discussion

415 Church St. NE, Suite 204
Vienna, VA 22180-4751